TLDR Exact Sciences is being acquired by Abbott Laboratories for $105 per share in cash, representing a 21.8% premium The deal values Exact Sciences at approximately $21 billion in equity value, with total transaction value reaching $23 billion including debt Exact Sciences’ flagship products Cologuard and Oncotype DX will join Abbott’s diagnostics portfolio The company [...] The post Exact Sciences (EXAS) Stock: Abbott to Acquire Cancer Diagnostics Company for $21 Billion appeared first on Blockonomi.TLDR Exact Sciences is being acquired by Abbott Laboratories for $105 per share in cash, representing a 21.8% premium The deal values Exact Sciences at approximately $21 billion in equity value, with total transaction value reaching $23 billion including debt Exact Sciences’ flagship products Cologuard and Oncotype DX will join Abbott’s diagnostics portfolio The company [...] The post Exact Sciences (EXAS) Stock: Abbott to Acquire Cancer Diagnostics Company for $21 Billion appeared first on Blockonomi.

Exact Sciences (EXAS) Stock: Abbott to Acquire Cancer Diagnostics Company for $21 Billion

TLDR

  • Exact Sciences is being acquired by Abbott Laboratories for $105 per share in cash, representing a 21.8% premium
  • The deal values Exact Sciences at approximately $21 billion in equity value, with total transaction value reaching $23 billion including debt
  • Exact Sciences’ flagship products Cologuard and Oncotype DX will join Abbott’s diagnostics portfolio
  • The company is projected to generate more than $3 billion in revenue this year with high-teens organic growth
  • The transaction is expected to close in the second quarter of 2026 after shareholder approval

Exact Sciences will be acquired by Abbott Laboratories in a deal announced Thursday. The transaction values the cancer diagnostics company at approximately $21 billion in equity.

Abbott will pay $105 per share in cash to Exact Sciences shareholders. This represents a premium of about 21.8% over Wednesday’s closing price of $86.18.

Shares of Exact Sciences rose more than 17% to $101.40 in premarket trading following the announcement. The stock gain reflects investor approval of the buyout terms.


EXAS Stock Card
Exact Sciences Corporation, EXAS

The total transaction value reaches up to $23 billion when including Exact Sciences’ estimated net debt of about $1.8 billion. Abbott will assume this debt as part of the acquisition.

Exact Sciences brings two major cancer screening products to Abbott. The first is Cologuard, a non-invasive colorectal cancer screening test.

Home-Based Cancer Screening

Cologuard allows patients to screen for colorectal cancer from home. The test requires only a stool sample that patients mail to a lab.

This contrasts with traditional colonoscopy procedures. Those require bowel preparation, sedation, and a clinical visit.

Colorectal cancer is the second-leading cause of cancer-related deaths worldwide. The home-based screening option has driven strong adoption of Cologuard.

The acquisition also includes Oncotype DX. This test screens for early-stage breast cancer.

Exact Sciences is projected to generate more than $3 billion in revenue this year. The company is growing at a high-teens organic rate.

Financial Impact on Combined Company

Abbott’s diagnostics business will exceed $12 billion in annual sales after the deal closes. This includes Exact Sciences’ revenue contribution.

Abbott’s existing diagnostics portfolio includes lab tests for heart disease and infections. The company also makes rapid tests for illnesses like COVID-19.

The deal helps Abbott offset declining revenue from COVID-19 testing kits. Cancer screening represents a faster-growing market segment.

Exact Sciences CEO Kevin Conroy will remain with the company in an advisory role. The company will maintain its presence in Madison, Wisconsin.

The transaction requires Exact Sciences shareholder approval. The deal is expected to close in the second quarter of 2026.

Abbott made the acquisition announcement Thursday morning. It marks Abbott’s first major push into cancer screening.

The post Exact Sciences (EXAS) Stock: Abbott to Acquire Cancer Diagnostics Company for $21 Billion appeared first on Blockonomi.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trust Wallet issues security alert: It will never ask users for their mnemonic phrase or private key.

Trust Wallet issues security alert: It will never ask users for their mnemonic phrase or private key.

PANews reported on January 17 that Trust Wallet issued a security warning on its X platform, stating that it will never ask users for their mnemonic phrases or
Share
PANews2026/01/17 21:10
Crypto Market Cap Edges Up 2% as Bitcoin Approaches $118K After Fed Rate Trim

Crypto Market Cap Edges Up 2% as Bitcoin Approaches $118K After Fed Rate Trim

The global crypto market cap rose 2% to $4.2 trillion on Thursday, lifted by Bitcoin’s steady climb toward $118,000 after the Fed delivered its first interest rate cut of the year. Gains were measured, however, as investors weighed the central bank’s cautious tone on future policy moves. Bitcoin last traded 1% higher at $117,426. Ether rose 2.8% to $4,609. XRP also gained, rising 2.9% to $3.10. Fed Chair Jerome Powell described Wednesday’s quarter-point reduction as a risk-management step, stressing that policymakers were in no hurry to speed up the easing cycle. His comments dampened expectations of more aggressive cuts, limiting enthusiasm across risk assets. Traders Anticipated Fed Rate Trim, Leaving Little Room for Surprise Rally The Federal Open Market Committee voted 11-to-1 to lower the benchmark lending rate to a range of 4.00% to 4.25%. The sole dissent came from newly appointed governor Stephen Miran, who pushed for a half-point cut. Traders were largely prepared for the move. Futures markets tracked by the CME FedWatch tool had assigned a 96% probability to a 25 basis point cut, making the decision widely anticipated. That advance positioning meant much of the potential boost was already priced in, creating what analysts described as a “buy the rumour, sell the news” environment. Fed Rate Decision Creates Conditions for Crypto, But Traders Still Hold Back Andrew Forson, president of DeFi Technologies, said lower borrowing costs would eventually steer more money toward digital assets. “A lower cost of capital indicates more capital flows into the digital assets space because the risk hurdle rate for money is lower,” he noted. He added that staking products and blockchain projects could become attractive alternatives to traditional bonds, offering both yield and appreciation. Despite the cut, crypto markets remained calm. Open interest in Bitcoin futures held steady and no major liquidation cascades followed the Fed’s decision. Analysts pointed to Powell’s language and upcoming economic data as the key factors for traders before building larger positions. Powell’s Caution Tempers Immediate Impact of Fed Rate Move on Crypto Markets History also suggests crypto rallies after rate cuts often take time. When the Fed eased in Dec. 2024, Bitcoin briefly surged 5% cent before consolidating, with sustained gains arriving only weeks later. This time, market watchers are bracing for a similar pattern. Powell’s insistence on caution, combined with uncertainty around inflation and growth, has kept short-term volatility muted even as sentiment for risk assets improves. BitMine’s Tom Lee this week predicted that Bitcoin and Ether could deliver “monster gains” in the next three months if the Fed continues on an easing path. His view echoes broader expectations that liquidity-sensitive assets will outperform once the cycle gathers pace. For now, the crypto sector has digested the Fed’s move with restraint. Traders remain focused on signals from the central bank’s October meeting to determine whether Wednesday’s step marks the beginning of a broader policy shift or just a one-off adjustment
Share
CryptoNews2025/09/18 13:14
Trust Wallet Alerts Users After Security Incident

Trust Wallet Alerts Users After Security Incident

The post Trust Wallet Alerts Users After Security Incident appeared on BitcoinEthereumNews.com. Key Points: Trust Wallet issues alert after $7 million theft from
Share
BitcoinEthereumNews2026/01/17 21:43